Labcorp sets 5-8% revenue CAGR through 2029, reaffirms FY26 guidance
- Labcorp reaffirms full-year 2026 financial guidance
- Targets 5% to 8% compound annual revenue growth through 2029
- Projects 8.5% to 11.5% compound annual adjusted EPS growth
- Highlights strategic focus on diagnostics, biopharma, and technology

*this image is generated using AI for illustrative purposes only.
Labcorp (NYSE: LH) reaffirmed its full-year 2026 guidance while unveiling a long-term financial outlook through 2029. The global laboratory services provider outlined compound annual revenue growth of 5% to 8% and adjusted earnings per share (EPS) growth of 8.5% to 11.5%.
The company announced these projections ahead of its 2026 Investor Day, scheduled for 9 am ET on Sept. 10, 2026, in Burlington, N.C.
Strategic Growth Priorities
Labcorp stated that its long-term value creation framework is driven by sustainable growth, strong cash flow generation, and disciplined capital deployment. The firm highlighted its differentiated platform, which it claims is powered by science, technology, and global scale.
Management emphasized the company’s position at the intersection of diagnostics, biopharma, science, and technology as a key driver for creating long-term value for customers and shareholders.
What the Numbers Show
The disclosed guidance indicates a targeted acceleration in earnings growth relative to top-line expansion. With adjusted EPS CAGR projected at 8.5% to 11.5% against a revenue CAGR of 5% to 8%, the outlook implies an expected margin expansion or operational leverage over the four-year period through 2029.
Which specific segments within Labcorp's biopharma and diagnostics divisions are expected to drive the projected 8.5% to 11.5% EPS growth?
How does Labcorp plan to achieve margin expansion through operational leverage amidst potential healthcare cost containment pressures?
What role will emerging technologies, such as AI-driven diagnostics or genomic sequencing, play in sustaining the 5% to 8% revenue CAGR through 2029?



























